Camurus Annual Report for 2016 released

Lund — 30 March 2017 —  Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2016 now is available at the company’s website: www.camurus.com

For more information:
Fredrik Tiberg, President & CEO 
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com   

Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

About Camurus
Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com